Oculis Holding (CR5) Price & Analysis

2 Followers

CR5 Stock Chart & Stats

€9.00

-€0.56(-5.86%)

At close: Jul 30 4:00 PM EDT

€9.00

-€0.56(-5.86%)

Day’s Range― - ―

52-Week Range€8.82 - €29.30

Previous CloseN/A

Volume0.00

Average Volume (3M)26.00

Market Cap

€760.54M

Enterprise Value€569.93

Total Cash (Recent Filing)€8.00K

Total Debt (Recent Filing)€2.54M

Price to Earnings (P/E)―

Beta0.40

Next Earnings

Nov 05, 2026

EPS Estimate

-0.43

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.40

Shares Outstanding67,792,175

10 Day Avg. Volume30

30 Day Avg. Volume26

Financial Highlights & Ratios

PEG Ratio0.60

Price to Book (P/B)4.22

Price to Sales (P/S)0.00

P/FCF Ratio-13.27

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€30.48

Price Target Upside238.71% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

EPS Forecast (FY)-1.34

Revenue Forecast (FY)€743.31K

Bulls Say, Bears Say

Bulls Say

Strong Balance Sheet And Low LeverageSubstantial equity, assets, and minimal leverage provide financial flexibility to fund clinical programs and absorb development uncertainty without immediate dependence on debt markets.

Late-stage Pipeline With Regulatory SupportLate-stage assets and supportive regulatory designations can accelerate development and improve the company’s competitive position if trials validate the therapies in neuro-ophthalmic markets.

Full Ownership May Improve Asset EconomicsOwning global rights could retain more future value from successful development, simplify control of commercialization, and reduce legacy obligations, although execution and closing conditions remain.

Bears Say

Minimal And Declining Commercial RevenueVery limited revenue shows the business remains dependent on successfully commercializing pipeline assets. Until launches generate scale, fixed development costs will continue to pressure margins and earnings.

Persistent Operating Cash BurnSustained cash consumption reduces the company’s financial base and may require future equity financing or other funding. Additional capital could dilute shareholders before products generate material cash flow.

Clinical And Regulatory Execution RiskThe investment case depends on trial outcomes, regulatory progress, and successful transaction closings. Delays, negative data, or approval setbacks could materially weaken the pipeline’s commercial potential.

Oculis Holding News

Oculis price target lowered to $20 from $23 at JPMorgan

JPMorgan lowered the firm’s price target on Oculis (OCS) to $20 from $23 and keeps an Overweight rating...

10d ago

OCS

Oculis price target lowered to $32 from $35 at BofA

BofA analyst Jason Gerberry lowered the firm’s price target on Oculis (OCS) to $32 from $35 and keeps...

16d ago

OCS

Oculis to acquire development, commercial rights to Privosegtor from Accure

Oculis (OCS) and Accure Therapeutics announced that Oculis and Accure have entered into an asset purchase agreement whereby,...

16d ago

OCS

Oculis reports Q2 EPS (16c), consensus (38c)

Riad Sherif, Chief Executive Officer of Oculis (OCS), stated, “We continue to advance and expand the Privosegtor neuroprotection...

19d ago

OCS

Oculis gets FDA pre-IND feedback regarding Privosegtor clinical development plan

Oculis (OCS) announced FDA pre-IND feedback regarding Privosegtor’s clinical development plan in acute multiple sclerosis relapses. Privosegtor is...

23d ago

OCS

Oculis: Advancing Privosegtor in Optic Neuritis and MS Relapses Supports Buy Rating and Unchanged $26 Price Target

Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on Oculis Holding and keeping the price target...

2d ago

OCS

Oculis to Acquire Full Rights to Privosegtor in Asset Deal with Accure Therapeutics

The latest announcement is out from Oculis Holding ( ($OCS) ). On August 10, 2026, Oculis Holding AG...

16d ago

OCS

Oculis Holding Reports Strong Equity Base and Updates SEC Risk Factors in Q2 2026 Filing

The latest update is out from Oculis Holding ( ($OCS) ). On August 6, 2026, Oculis Holding AG...

19d ago

OCS

Oculis: Privosegtor’s Pivotal MS Opportunity and FDA Alignment Underpin Unchanged $45 Price Target and Buy Rating

Oculis Holding, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Dolezal from...

20d ago

OCS

Oculis Advances Privosegtor Into Phase 3 Optic Neuritis Trial: What Investors Should Watch

Oculis Holding Ag ($OCS) announced an update on their ongoing clinical study. The study “A Randomized, Double-masked, Placebo-controlled...

2M ago

OCS

Oculis Updates Investor Presentation, Emphasizing Late-Stage Neuro-Ophthalmic Pipeline and Cash Runway

The latest announcement is out from Oculis Holding ( ($OCS) ). On June 25, 2026, Oculis Holding AG...

2M ago

OCS

Oculis price target lowered to $23 from $42 at JPMorgan

JPMorgan lowered the firm’s price target on Oculis (OCS) to $23 from $42 and keeps an Overweight rating...

3M ago

OCS

Oculis price target lowered to $38 from $49 at Baird

Baird lowered the firm’s price target on Oculis (OCS) to $38 from $49 and keeps an Outperform rating...

3M ago

OCS

Oculis price target lowered to $38 from $49 at Baird

Baird lowered the firm’s price target on Oculis (OCS) to $38 from $49 and keeps an Outperform rating...

3M ago

OCS

CR5 FAQ

What was Oculis Holding’s price range in the past 12 months?

Oculis Holding lowest stock price was €8.82 and its highest was €29.30 in the past 12 months.

What is Oculis Holding’s market cap?

Oculis Holding’s market cap is €760.54M.

When is Oculis Holding’s upcoming earnings report date?

Oculis Holding’s upcoming earnings report date is Nov 05, 2026 which is in 71 days.

How were Oculis Holding’s earnings last quarter?

Oculis Holding released its earnings results on Aug 06, 2026. The company reported -€0.17 earnings per share for the quarter, beating the consensus estimate of -€0.413 by €0.243.

Is Oculis Holding overvalued?

According to Wall Street analysts Oculis Holding’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Oculis Holding pay dividends?

Oculis Holding does not currently pay dividends.

What is Oculis Holding’s EPS estimate?

Oculis Holding’s EPS estimate is -0.43.

How many shares outstanding does Oculis Holding have?

Oculis Holding has 67,792,175 shares outstanding.

What happened to Oculis Holding’s price movement after its last earnings report?

Oculis Holding reported an EPS of -€0.17 in its last earnings report, beating expectations of -€0.413. Following the earnings report the stock price went up 1.97%.

Which hedge fund is a major shareholder of Oculis Holding?

Currently, no hedge funds are holding shares in DE:CR5

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Oculis Holding Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

36.01%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Oculis Holding

Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.

Oculis Holding (CR5) Earnings & Revenues

Historic Earnings Reports

CR5 Stock 12 Month Forecast

Average Price Target

€30.48

▲(238.71% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"€8","39":"€39","15.75":"€15.75","23.5":"€23.5","31.25":"€31.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":38.58166935,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€38.58</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30.484281955555552,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€30.48</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.1474086,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€17.15</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,15.75,23.5,31.25,39],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.56,11.792436103846153,14.024872207692308,16.257308311538463,18.489744415384614,20.72218051923077,22.954616623076923,25.187052726923078,27.419488830769232,29.651924934615387,31.88436103846154,34.11679714230769,36.349233246153844,{"y":38.58166935,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.56,11.169560150427351,12.7791203008547,14.38868045128205,15.998240601709401,17.60780075213675,19.217360902564103,20.82692105299145,22.4364812034188,24.04604135384615,25.6556015042735,27.265161654700847,28.874721805128203,{"y":30.484281955555552,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.56,10.143646815384615,10.727293630769232,11.310940446153847,11.894587261538462,12.478234076923076,13.061880892307691,13.645527707692308,14.229174523076923,14.812821338461537,15.396468153846154,15.980114969230769,16.563761784615384,{"y":17.1474086,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.65,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.1,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.35,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.8,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.9,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.8,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.5,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.6,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.55,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.56,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >